Skip to main content
SpringerLink
Log in

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

CD26 is a transmembrane glycoprotein whose role in various types of malignancies, along with the potential therapeutic and diagnostic targets, has been evaluated. Preoperative chemoradiotherapy (CRT) is an effective tool for local control of rectal cancer, but the rate of disease recurrence remains high. The aim of this study was to clarify the association between CD26 expression and rectal cancer after preoperative CRT.

Methods

A total of 85 patients with rectal cancer who had undergone preoperative CRT were enrolled in this study. We investigated CD26 expression in residual tumors and the surrounding stromal tissue using immunohistochemistry. Additionally, stromal CD26 gene expression was assessed by real-time quantitative polymerase chain reaction.

Results

Patients with high CD26 expression in cancer tissue more frequently had serosal invasion, vascular invasion, and a poor pathological response. High expression of CD26 in the tumor stroma was significantly correlated with histology and tumor recurrence. High CD26 expression in the stroma, but not the tumor itself, was significantly correlated with a poor prognosis. Patients expressing CD26 in the tumor stroma, based on transcriptional analysis, also had a significantly poorer prognosis than those without the expression. In multivariate analysis, lymph node metastasis and high stromal CD26 expression were identified as independent prognostic factors in patients with rectal cancer after neoadjuvant CRT.

Conclusion

Stromal CD26 expression after preoperative CRT was significantly associated with tumor recurrence and prognosis in rectal cancer patients. Our data suggest that stromal CD26 plays an important role and is a potential therapeutic target in tumor relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Article  CAS  PubMed  Google Scholar 

  2. van den Brink M, Stiggelbout AM, van den Hout WB et al (2004) Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 22:3958–3964

    Article  PubMed  Google Scholar 

  3. Guillem JG, Chessin DB, Cohen AM et al (2005) Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241:829–836 (discussion 836–828)

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123

    Article  CAS  PubMed  Google Scholar 

  5. Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701

    Article  PubMed  Google Scholar 

  6. Kelly T (2005) Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8:51–58

    Article  CAS  PubMed  Google Scholar 

  7. Cordero OJ, Salgado FJ, Nogueira M (2009) On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 58:1723–1747

    Article  CAS  PubMed  Google Scholar 

  8. Kikkawa F, Kajiyama H, Shibata K et al (2005) Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45–51

    Article  CAS  PubMed  Google Scholar 

  9. Lam CS, Cheung AH, Wong SK et al (2014) Prognostic significance of CD26 in patients with colorectal cancer. PLoS One 9:e98582

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ayude D, de la Paez Cadena M, Cordero OJ et al (2003) Clinical interest of the combined use of serum CD26 and alpha-l-fucosidase in the early diagnosis of colorectal cancer. Dis Markers 19:267–272

    Article  CAS  PubMed  Google Scholar 

  11. de la Haba-Rodriguez J, Macho A, Calzado MA et al (2002) Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma 49:307–311

    PubMed  Google Scholar 

  12. Cordero OJ, Imbernon M, Chiara LD et al (2011) Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol 2:245–261

    Article  PubMed  PubMed Central  Google Scholar 

  13. Pang R, Law WL, Chu AC et al (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6:603–615

    Article  CAS  PubMed  Google Scholar 

  14. Dang NH, Aytac U, Sato K et al (2003) T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121:857–865

    Article  PubMed  Google Scholar 

  15. Cro L, Morabito F, Zucal N et al (2009) CD26 expression in mature B-cell neoplasia: it’s possible role as a new prognostic marker in B-CELL. Hematol Oncol 27:140–147

    Article  CAS  PubMed  Google Scholar 

  16. Carlucci F, Marinello E, Tommassini V et al (2009) A 57-gene expression signature in B-cell chronic lymphocytic leukemia. Biomed Pharmacother 63:663–671

    Article  CAS  PubMed  Google Scholar 

  17. Havre PA, Abe M, Urasaki Y et al (2009) CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 101:983–991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yamaguchi U, Nakayama R, Honda K et al (2008) Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 26:4100–4108

    Article  CAS  PubMed  Google Scholar 

  19. Lu Z, Qi L, Bo XJ et al (2013) Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. J Res Med Sci 18:647–652

    PubMed  PubMed Central  Google Scholar 

  20. Khin EE, Kikkawa F, Ino K et al (2003) Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol 188:670–676

    Article  CAS  PubMed  Google Scholar 

  21. Kajiyama H, Kikkawa F, Ino K et al (2003) Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. Adv Exp Med Biol 524:245–248

    Article  CAS  PubMed  Google Scholar 

  22. Sun YX, Pedersen EA, Shiozawa Y et al (2008) CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 25:765–776

    Article  CAS  PubMed  Google Scholar 

  23. Tan CW, Lee YH, Tan HH et al (2014) CD26/DPPIV down-regulation in endometrial stromal cell migration in endometriosis. Fertil Steril 102(167–177):e169

    Google Scholar 

  24. Saigusa S, Toiyama Y, Tanaka K et al (2011) Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol 38:655–663

    Article  CAS  PubMed  Google Scholar 

  25. Saigusa S, Inoue Y, Tanaka K et al (2013) Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol 2:99–104

    PubMed  PubMed Central  Google Scholar 

  26. Ryan R, Gibbons D, Hyland JM et al (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141–146

    Article  CAS  PubMed  Google Scholar 

  27. Gonzalez-Gronow M, Kaczowka S, Gawdi G et al (2008) Dipeptidyl peptidase-IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 13:1610–1618

    Article  CAS  PubMed  Google Scholar 

  28. Havre PA, Abe M, Urasaki Y et al (2008) The role of CD26/dipeptidyl peptidase-IV in cancer. Front Biosci 13:1634–1645

    Article  CAS  PubMed  Google Scholar 

  29. Sedo A, Stremenova J, Busek P et al (2008) Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opin Med Diagn 2:677–689

    Article  CAS  PubMed  Google Scholar 

  30. O’Brien P, O’Connor BF (2008) Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 1784:1130–1145

    Article  PubMed  Google Scholar 

  31. Scanlan MJ, Raj BK, Calvo B et al (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 91:5657–5661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen WT, Kelly T (2003) Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 22:259–269

    Article  PubMed  Google Scholar 

  33. Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91:439–442

    Article  CAS  PubMed  Google Scholar 

  34. Moehrle MC, Schlagenhauff BE, Klessen C et al (1995) Aminopeptidase M and dipeptidyl peptidase-IV activity in epithelial skin tumors: a histochemical study. J Cutan Pathol 22:241–247

    Article  CAS  PubMed  Google Scholar 

  35. Wilson MJ, Haller R, Li SY et al (2005) Elevation of dipeptidyl peptidase-IV activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol 174:1124–1128

    Article  CAS  PubMed  Google Scholar 

  36. Bogenrieder T, Finstad CL, Freeman RH et al (1997) Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase-IV in benign and malignant human prostate tissue. Prostate 33:225–232

    Article  CAS  PubMed  Google Scholar 

  37. Wesley UV, McGroarty M, Homoyouni A (2005) Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 65:1325–1334

    Article  CAS  PubMed  Google Scholar 

  38. Femia AP, Raimondi L, Maglieri G et al (2013) Long-term treatment with Sitagliptin, a dipeptidyl peptidase-IV inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 133:2498–2503

    Article  CAS  PubMed  Google Scholar 

  39. Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Susumu Saigusa, Yuji Toiyama, Koji Tanaka, Yasuhiro Inoue, Koichiro Mori, Shozo Ide, Hiroki Imaoka, Mikio Kawamura, Yasuhiko Mohri & Masato Kusunoki

Authors
  1. Susumu Saigusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuji Toiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiro Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koichiro Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shozo Ide
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Imaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mikio Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasuhiko Mohri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masato Kusunoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susumu Saigusa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saigusa, S., Toiyama, Y., Tanaka, K. et al. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy. Int J Clin Oncol 21, 350–358 (2016). https://doi.org/10.1007/s10147-015-0902-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0902-8

Keywords

Search

Navigation